AstraZeneca in focus ahead of Oxford Covid-19 vaccine data next week

Pressure is growing on AstraZeneca to deliver positive results from early tests evaluating the coronavirus vaccine it’s developing with University of Oxford researchers as investors await data expected on Monday.

The UK pharma company is staying quiet after British media reports said results of phase 1 tests to be published in The Lancet medical journal were promising, driving the shares up this week.